We are pleased to see the updated results from Part A of the RAMP 201 (ENGOTov60/GOG3052) trial in low-grade serous ovarian cancer (LGSOC).   

Anna Hudson our Head of Support Services said: ‘It’s great to hear such encouraging results from the RAMP 201 trial. We know from our members that experiencing a recurrence of ovarian cancer can be a really anxious time and those with rarer types of ovarian cancer, such as low grade, worry that there will be fewer effective treatment options available to them. We hope this will ultimately lead to expanded treatment choices for those with recurrent low grade ovarian cancer.”

The results from the trial are available to view via this link: investor.verastem.com/news-releases/news-release-details/updated-data-part-verastem-oncologys-ramp-201-trial-show. The results will be presented by Dr. Susana Banerjee, MBBS, MA PhD, FRCP, global and lead investigator of the study, in a poster discussion at ASCO on Monday, June 5.  For more information please contact our support team on 0800 008 7054.